Liu et al. recently reported the safety and efficacy of cord blood derived CD19 CAR NK cells in patients with relapsed/refractory CD19 B-cell NHL and chronic lymphocytic leukemia (CLL) [13••]. This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.